Claims

1. Use of vitamin D and one or more agent selected from the group consisting of: epigallocatechin gallate (EGCG), catechin, gallocatechin and epicatechin gallate (ECG), in the manufacture of a medicament for the prevention, control and/or treatment of a uterine fibroid or a fibroadenoma.

2. The use according to claim 1, wherein said one or more agent is selected from the group consisting of: epigallocatechin-3-gallate, (–)-epigallocatechin-3-gallate, (–)-gallocatechin-3-O-gallate (GCG), (–)-gallocatechin-3-gallate, (+)-catechin (C), (–)-epicatechin (EC), (+)-gallocatechin (GC), (–)-epigallocatechin (EGC), (–)-epicatechin-3-gallate, (–)-catechin-3-gallate and (+)-catechin-3-gallate.

3. The use according to claim 1, wherein said fibroid is in a fibroblast-containing tissue.

4. The use according to claim 1, wherein said vitamin D is in an amount of from 1 µg to 100 µg per day, and/or said one or more agent is in an amount of from 5 mg to 1000 mg per day and/or said vitamin D and said one or more agent are in a weight ratio of from 1 : 50 to 1 : 1000000.

5. The use according to claim 4, wherein said vitamin D is in an amount of approximately 50 µg per day, and/or said one or more agent is in an amount of approximately 300 mg per day and/or said vitamin D and said one or more agent are in a weight ratio of approximately 1 : 6000, 1 : 50, 1 : 2000, 1 : 2500, 1 : 3000, 1 : 5000, 1 : 7000, 1 : 10000, or 1 : 1000000.

6. Use of Vitamin D, one or more agent selected from the group consisting of: epigallocatechin gallate (EGCG), catechin, gallocatechin and epicatechin gallate (ECG), and at least one further agent selected from the group consisting of: vitamin B, a polyphenol and DL-alpha-tocopherol, in the manufacture of a medicament for the prevention, control and/or treatment of a uterine fibroid or a fibroadenoma.

7. The use according to claim 6, wherein said vitamin D, said one or more agent and said at least one further agent are in a weight ratio of from 1 : 5000 : 100 to 1 : 10000 : 1000.

8. The use according to claim 7, wherein said vitamin D, said one or more agent and said at least one further agent are in a weight ratio of approximately 1 : 6000 : 200, 1 : 5000 : 1000, 1 : 10000 : 100 or 1 : 10000 : 1000.

9. The use according to claim 6, wherein said at least one further agent is vitamin B6.

10. The use according to claim 9, wherein said vitamin B6 is in an amount of from 1 to 100 mg per day.

11. The use according to claim 6, wherein said at least one further agent is in an amount of approximately 1 to 10 mg per day.

12. The use according to claim 11, wherein said at least one further agent is in an amount of approximately 1 to 5 mg per day.

13. The use according to any one of the preceding claims, wherein said one or more agent is epigallocatechin gallate (EGCG) and/or wherein said fibroid is a uterine fibroid.

14. The use according to any one of the preceding claims, wherein said one or more agent is in the form of a tea plant leaf or of an extract of a tea plant leaf.

15. The use according to claim 14, wherein said tea plant leaf is a green tea plant leaf.

16. The use according to any one of the preceding claims, wherein said agent is in an amount of from 30 wt% to 95 wt%, preferably approximately 30 wt%, 45 wt%, 50 wt% or 95 wt%.

17. The use according to any one of the preceding claims, wherein said vitamin D and said one or more agent reduce the release of fibronectin and/or collagen.

18. The use according to any one of the preceding claims, wherein said fibroid is a uterine fibroid and said prevention, control and/or treatment of a uterine fibroid comprises the prevention, control and/or treatment of at least one symptom of a uterine fibroid, said symptom being preferably selected from the group consisting of: menorrhagia, dysmenorrhea, intermenstrual bleeding, pelvic pain (acute or chronic), painful sexual intercourse, anemia, a compromised reproductive function, subfertility, infertility, early pregnancy loss, recurrent abortion, preterm delivery and a pregnancy complication, fatigue and a pressure symptom such as bloatedness, increased urinary frequency, bowel disturbance.

19. The use according to any one of the preceding claims, wherein said vitamin D and said one or more agent are to be administered simultaneously and/or orally and/or twice a day.

20. Use of a composition comprising:
- vitamin D,
- one or more agent selected from the group consisting of: epigallocatechin gallate (EGCG), catechin, gallocatechin and epicatechin gallate (ECG),
- an excipient or a diluent, and
- optionally at least one further agent,
in the manufacture of a medicament for the prevention, control and/or treatment of a uterine fibroid or a fibroadenoma.

21. The use according to claim 20, wherein said one or more agent is selected from the group consisting of: epigallocatechin-3-gallate, (–)-epigallocatechin-3-gallate, (–)-gallocatechin-3-O-gallate (GCG), (–)-gallocatechin-3-gallate, (+)-catechin (C), (–)-epicatechin (EC), (+)-gallocatechin (GC), (–)-epigallocatechin, (–)-epicatechin-3-gallate, (–)-catechin-3-gallate and (+)-catechin-3-gallate.

22. The use according to any one of claims 20 and 21, wherein said one or more agent is in the form of a tea plant leaf or of an extract of a tea plant leaf.

23. The use according to claim 20, wherein said excipient and/or diluent is selected from the group consisting of: calcium phosphate, dicalcium phosphate, microcrystalline cellulose, magnesium stearate, silicon dioxide, sucrose, gum arabic, corn starch, medium-chain triglycerides, tricalcium phosphate, cross-linked sodium carboxymethylcellulose, hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide, polyvinylpyrrolidone, talc, erythritol, xylitol, steviol glycosides and sucralose.

24. The use according to claim 20, wherein said at least one optional further agent is selected from the group consisting of: vitamin B, a polyphenol and DL-alpha-tocopherol.

25. The use according to claim 20, wherein said fibroid is in a fibroblast-containing tissue.

26. The use according to claim 20, wherein said composition is to be administered orally.

27. The use according to claim 20, wherein said composition is in the form of a tablet, a hard capsule, a soft gel capsule, a powder, a syrup, a cachet, a troche, a lozenge or a pastille.

28. The use according to claim 20, in combination with a further therapeutic intervention, said further therapeutic intervention selected from the group consisting of: surgery, a gonadotropin-releasing hormone agonist, a selective progesterone receptor modulator, an anti-hormonal agent, a hormone, an anti-inflammatory painkiller and tranexamic acid.

29. The use according to any one of claims 20 to 28, wherein the composition is a pharmaceutical composition, a supplement, a food product or a drink product.

30. The use according to any one of claims 20 to 29, wherein the composition comprises: EGCG in the form of an extract of a green tea plant leaf, Microcrystalline

cellulose, Calcium phosphate or Dicalcium phosphate, Vitamin D3, Vitamin B6, Magnesium stearate and Silicon dioxide.